ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / NVCR
KMTS (50) TNDM (28) LMAT (67) XRAY (32) ⌘ Pro Terminal β†’

NovoCure Limited (NVCR) β€” RQD Stock Rating Cockpit

$13.21 +0.46% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.20

NovoCure Limited (NVCR) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $1.54B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVCR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NVCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, NovoCure Limited (NASDAQ: NVCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $13.21 (+0.46% 1D, market cap $1.54B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NVCR ranks #973 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NVCR compare to KMTS and TNDM in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), NVCR carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 74.5%, and ROIC of -27.5%. By comparison, KMTS (Kestra Medical Technologies Ltd.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.77B) and TNDM (Tandem Diabetes Care Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, LMAT leads on earnings multiple (33.8x) while LMAT leads on capital efficiency (14.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVCR?
β–Ό

Per NVCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645113), NovoCure Limited generated $655.4M in revenue (+8.3% YoY), -$136.2M in net income, and -$75.7M in free cash flow against $804.3M in total assets and $195.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.20 (-0.11%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (20/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510020
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (3)Whales (4)SEC (8)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.1% Base Target
$23 Bull$11 Base$9 Bear
πŸ“¬ FREE NVCR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NVCR)Realized 20D OHLCV Swing Band: Β±11%
Deterministic 5-Pillar Attribution (20/100 Composite)
πŸ” WHY NVCR SCORES 20/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (40% of score)

Altman Z-Score 0.54 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 6/9

β–² #2 Bullish Driver: Cash Engine Quality+4/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 74.5% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$14.30+9.9% Next Q
Q2 (-2Q)
25
Grade E$15.71-6.9% Next Q
Q3 (-1Q)
23
Grade E$14.62-9.6% Next Q
Current
20
Grade E$13.21-11.8% Hist 90D Ξ±
Trajectory: E (28) β†’ E (20)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NVCR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NVCR currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.64) and Max Pain ($13.87) forces dealer call-delta covering toward $22.52.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVCRβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNVCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
34.330 Oversold Β· 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.54>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE29% OF RANGE
L: $10$13.21H: $21
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 1 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NVCR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-27.5% ROIC with 74.5% gross margin and -4.96% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.54 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (18)

7/40 institutional & smart-money positioning score with 4/20 macro alignment.

Bull Case: Why Buyers Like NVCR
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCR)

  • βœ“Walkthrough of NVCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NVCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.97%β–Ό DESCENDING CHANNEL
2026-11-03O $13.11H $13.21L $13.11C $13.21VOL 1.97M
RES: $15.43SUP: $11.71SMA50: $15.64SMA200: $14.81
$22.12$19.34$16.55$13.77$10.99RES $15.43SUP $11.71$13.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NVCR Butterfly Map β†’ + Track NVCR β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NVCR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NVCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCR)

Health Care Rank #973 of 1015 βš”οΈ KMTS vs NVCR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NVCR vs. KMTS, TNDM, LMAT, XRAY)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NovoCure Limited (NVCR) ranks #973 by composite RQD confidence (20/100, grade E) and #298 by equity capitalization ($1.54B). Within this direct 5-issuer industry benchmark cohort, LMAT leads on earnings valuation at 33.8x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with NVCR at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NVCR ACTIVE
NovoCure Limited
E 20/100 β€” 74.5% -27.5% +0.46% $1.54B Benchmark Subject
KMTS
Kestra Medical Technologies Ltd.
D 50/100 β€” 51.4% -35.0% +0.40% $1.77B /kmts-vs-nvcr β†’
TNDM
Tandem Diabetes Care Inc.
E 28/100 β€” 53.8% -35.0% -2.30% $1.33B /tndm-vs-nvcr β†’
LMAT
LeMaitre Vascular Inc.
C+ 67/100 33.8x 71.5% 14.7% +0.40% $1.85B /lmat-vs-nvcr β†’
XRAY
DENTSPLY SIRONA Inc.
E 32/100 β€” 50.0% -11.0% +3.88% $1.90B /xray-vs-nvcr β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001645113 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NovoCure Limited (NVCR) reported GAAP revenue of $655.4M (+8.3% vs. FY2024 revenue of $605.2M , and +28.7% cumulative change since FY2023) , GAAP net income of -$136.2M, operating cash flow of -$49.0M, and free cash flow of -$75.7M (-9.3% YoY). On the balance sheet, NVCR closed FY2025 with $804.3M in total assets against $195.0M in total debt (Altman Z-Score: 0.54, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $655.4M -$136.2M -$49.0M -$75.7M $804.3M $195.0M
FY2024 (FY) 2024-12-31 $605.2M -$169.0M -$26.4M -$69.2M $1.24B $97.3M
FY2023 (FY) 2023-12-31 $509.3M -$207.0M -$73.3M -$73.3M β€” β€”

3. NVCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NovoCure Limited (NASDAQ: NVCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $13.21 (+0.46% 1D, market cap $1.54B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NVCR ranks #973 in composite RQD confidence.

How does NVCR compare to KMTS and TNDM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NVCR carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 74.5%, and ROIC of -27.5%. By comparison, KMTS (Kestra Medical Technologies Ltd.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.77B) and TNDM (Tandem Diabetes Care Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B). Among the 5-stock peer group, LMAT leads on earnings multiple (33.8x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NVCR?

Per NVCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645113), NovoCure Limited generated $655.4M in revenue (+8.3% YoY), -$136.2M in net income, and -$75.7M in free cash flow against $804.3M in total assets and $195.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NVCR trading relative to its 50-day, 200-day, and 52-week technical levels?

NVCR last traded at $13.21 (+0.46% on volume of 1,647,292 shares), positioning the stock -15.54% below its 50-day simple moving average ($15.64) and -10.80% below its 200-day simple moving average ($14.81). Across its 52-week range of $9.82 to $21.45, NVCR sits at the 29.1% percentile with a 14-day RSI of 34.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.0% ($11.76 to $14.66).

Direct Sub-Reports: NVCR RQD Cockpit NVCR 12M Forecast NVCR Earnings & Move NVCR Dividends & DRIP NVCR Insiders & 13F NVCR Whale Options NVCR Profit Sankey NVCR News & Why
ROARABLE RATING BRIEF β€’ RQD 20/100 (E) βœ“ SEC XBRL & RQD VERIFIED

NVCR β€” NovoCure Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NovoCure Limited (NVCR) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $13.21 (+0.46% 1D, market capitalization $1.54B).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -27.5%, gross margin of 74.5%, operating margin of -23.5%, and free cash flow yield of -4.96%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.54, Piotroski F-Score of 6/9, and Debt/Equity of 0.57x.

2. Business Model, Unit Margins & SEC Financial Trajectory

β€” is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, with a market capitalization of $1.5B. Per the market data, the gross margin is 74.5%, indicating a high gross margin profile, but the source does not specify what generates that revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NovoCure Limited (NVCR) reported $655.4M in annual revenue (up from $605.2M in FY2024, +8.3% YoY) and -$136.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($509.3M revenue, -$207.0M net income) through FY2025, NVCR scaled operating cash flow to -$49.0M and free cash flow to -$75.7M, backed by $804.3M in total assets against $195.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.96% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $9.82 – $21.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -23.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” The Butterfly Supply-Chain Graph records the supply chain as NONE, with no upstream or downstream links and no proprietary signals.

  • Key Question #1: Can NVCR sustain or expand its -23.5% operating margin and -27.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $655.4M and free cash flow of -$75.7M, how will capital allocation balance growth reinvestment against $195.0M in total debt?
  • Key Question #3: How sensitive is NVCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NVCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NovoCure Limited (NVCR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NVCR Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVCR Bull vs. Bear Conversation Board β€” What's Your Call at $13.21?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVCR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NVCR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $15.65 (+19.0%)
πŸ“Œ Pinned Debate

Revenue grew from $509.3M in FY 2023 to $655.4M in FY 2025 while operating losses narrowed from -$232.9M to -$153.8M.

Don't sleep on NVCR's setup in Health Care. Revenue grew from $509.3M in FY 2023 to $655.4M in FY 2025 while operating losses narrowed from -$232.9M to -$153.8M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (20/100) backs up the fundamental quality.

VolSurface_Trader πŸ‚ BULL

@SkepticalCFA Shorting a 4/20 institutional whale-flow stock at $13.15 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $10.39 (-21.0%)
Spot @ $13.15

Cash fell from $163.8M to $93.5M while debt rose from $97.3M to $195.0M, with an Altman Z-Score of 0.54 and negative free cash flow.

Sitting on the sidelines or leaning short NVCR above $13.15. Cash fell from $163.8M to $93.5M while debt rose from $97.3M to $195.0M, with an Altman Z-Score of 0.54 and negative free cash flow.. Until Fundamental Cash Engine (1/20) and FCF yield (-4.96%) inflect higher, upside is capped near $21.45.

LIVE TAPE